Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer
A phase 2 trial of Acasunlimab, Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by Genmab, active and no longer recruiting.
Overview
Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer is a phase 2 interventional study registered as NCT05117242 by Genmab, with 125 participants enrolled, started 2021-10-27 and due to reach its primary completion in 2024-12-02. Interventions recorded: Acasunlimab, Pembrolizumab. Conditions listed: Non Small Cell Lung Cancer Metastatic. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialTrial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)
Shares Acasunlimab, Genmab, Non-small-cell lung cancer.
- TrialStudy to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
Shares Genmab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialPhase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combina
Shares Genmab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialGEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
Shares Genmab, Pembrolizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialEfficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
Shares Genmab, Pembrolizumab, Non-small-cell lung cancer.
- TrialA Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Shares Genmab, Pembrolizumab.
- TrialLiGeR-HN1
Shares Genmab, Pembrolizumab.
- TreatmentMCLA-129
Shares Genmab, Non-small-cell lung cancer.